<DOC>
	<DOCNO>NCT02500251</DOCNO>
	<brief_summary>This study prospective , open label , phase I/II pilot study .</brief_summary>
	<brief_title>Belimumab Impacting Transplant Eligibility</brief_title>
	<detailed_description>This study prospective , open label , phase I/II pilot study . For Treatment Groups A B , duration study include 5 month enrollment period approximately 7 month follow-up . For Treatment Group C , duration study include 3 month enrollment period approximately 7 month follow-up .</detailed_description>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<mesh_term>Belimumab</mesh_term>
	<criteria>1 . Patient 18 65 year age , inclusive , endstage renal disease await kidney transplantation . 2 . Patient eligible living donor : DSA live donor &gt; 5,000 MFI positive T B cell flow cytometry crossmatch . 3 . Patient kidney transplant wait list await decease donor transplant iAb &gt; 8,000 MFI current peak calculate panel reactive antibody ( cPRA ) &gt; 20 % . 4 . Voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care . 5 . Female subject either postmenopausal one year prior screen surgically sterilize . Women childbearing potential ( WOCBP ) must become pregnant must sexually inactive abstinence ( start 2 week prior 1st belimumab and/or bortezomib dose ) use contraceptive method failure rate &lt; 1 % ( start 1 month prior 1st belimumab and/or bortezomib dose ) duration study 16 week last belimumab and/or bortezomib dose . WOCBP must negative urine serum pregnancy test screen &lt; 7 day prior first belimumab and/or bortezomib dose . 6 . Male subject , even surgically sterilize ( i.e. , status post vasectomy ) must agree 1 following : practice effective barrier contraception entire study treatment period minimum 16 week last dose belimumab and/or bortezomib , completely abstain heterosexual intercourse . 7. Review pretransplant medical clearance patient 's transplant nephrologist assure patient medically acceptable study entry . 8 . Cardiac evaluation transplant nephrologist clearance document write participate study . 1 . Know hypersensitivity bortezomib , boron mannitol , rituximab , belimumab component . 2 . Have history anaphylactic reaction parenteral administration contrast agent , human murine proteins monoclonal antibody . 3 . Subjects judge investigator significant risk fail comply requirement protocol unable cooperate communicate investigator . 4 . Abnormal ECG clinically significant ventricular arrhythmia conduction abnormality opinion investigator warrant exclusion subject trial . 5 . Myocardial infarction within 6 month prior enrollment New York Heart Association ( NYHA ) Class III IV heart failure ( Appendix A ) , uncontrolled angina , severe uncontrolled ventricular arrhythmia , electrocardiographic evidence acute ischemia active conduction system abnormality . Prior study entry , abnormality ECG perform within 30 day consent document investigator patient 's transplant nephrologist medically relevant . 6 . Patient Grade 2 peripheral neuropathy CTCAE criterion within 14 day enrollment . 7 . Patients absolute neutrophil count &lt; 1,000/mm3 platelet count &lt; 75,000/mm3 within 30 day consent . 8 . Patient receive intravenous cyclophosphamide within 180 day prior belimumab , biologic investigational agent within 365 day prior belimumab , nonbiologic investigational agent within 30 day ( 5 halflives , whichever great ) prior belimumab . 9 . Receipt live vaccine within 30 day prior initiation study treatment . 10 . Received blood transfusion within 30 day prior trial entry . 11 . Have intercurrent significant medical ( renal disease ) psychiatric illness investigator considers would make candidate unsuitable study . 12 . Have historically positive HIV test test positive HIV within one year consent . 13 . Hepatitis status : . Hepatitis B : Serologic evidence current past Hepatitis B ( HB ) infection base result test HBsAg antihepatitis B core ( HBc ) follow : . Patients positive HBsAg HBcAb historically test perform within one year consent exclude ii . Hepatitis C : Positive test Hepatitis C antibody test perform within one year consent . 14 . History malignancy within past 5 year consider cure , exception localize basal cell carcinoma skin ( excise â‰¥ 2 year prior randomization ) . 15 . Evidence severe liver disease abnormal liver profile ( aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) total bilirubin &gt; 1.5 time upper limit normal ( ULN ) ) test perform within 30 day consent . 16 . Infection history : ) Currently suppressive therapy chronic infection ( tuberculosis , pneumocystis , cytomegalovirus , herpes simplex virus , herpes zoster atypical mycobacteria ) . b ) Hospitalization treatment infection within 60 day Day 0. c ) Use parenteral ( IV IM ) antibiotic ( antibacterial , antiviral , antifungal , anti parasitic agent ) within 60 day Day 0 . 17 . Pregnant nursing ( lactate ) woman woman might become pregnant study . 18 . Have evidence serious suicide risk include history suicidal behavior last 6 month and/or suicidal ideation last 2 month investigator 's judgment , pose significant suicide risk . 19 . Have history primary immunodeficiency . 20 . Have significant IgG deficiency ( IgG level &lt; 400 mg/dl ) IgA deficiency ( IgA level &lt; 10 mg/dL ) . 21 . Have current drug alcohol abuse dependence , history drug alcohol abuse dependence within 364 day prior Day 0 . 22 . Have clinically significant abnormal laboratory value opinion investigator warrant exclusion subject trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Transplantation</keyword>
	<keyword>belimumab</keyword>
	<keyword>Velcade</keyword>
</DOC>